Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 6, 2026Clinical and Experimental MedicineOpen Access

Venetoclax, azacitidine, and chidamide in combination with cytarabine, aclarubicin, and G-CSF as induction chemotherapy for myelodysplasia-related acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

LLLei LvJYJingjing YangQLQingyang Liu

Discussion

Loading...

Member takes

Overview

Retrospective study shows superior outcomes in AML patients using CACAG-VEN regimen, suggesting benefits over standard treatment.

Key Points

  • This study aims to evaluate the efficacy and safety of the CACAG-VEN regimen in treating AML-MR.
  • Retrospective analysis of 30 AML-MR patients treated with CACAG-VEN from 2023 to 2024.
  • Cohort comparison with 30 patients receiving standard '3 + 7' regimen from 2018 to 2022.
  • Primary endpoint was complete remission rate after one induction cycle.
  • CACAG-VEN achieved a complete remission rate of 83.3% (95% CI, 66.4-92.7).
  • 1-year overall survival for CACAG-VEN was 90.0% (95% CI: 72.1-96.7).
  • CACAG-VEN showed superior response rates compared to '3 + 7' regimen (CR: 55.7%, p = 0.003).

Cite This Study

Lv et al. (2026) studied this question.

synapsesocial.com/papers/6a23b96a71a5da9775e754dchttps://doi.org/10.1007/s10238-026-02200-9
View Full Paper
Ask AI
Bookmark
Share